Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.

MLA

Abdelmalek, Carine M., et al. “Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.” Journal of Medicinal Chemistry, vol. 65, no. 6, Mar. 2022, pp. 4616–32. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.1c01646.

APA

Abdelmalek, C. M., Hu, Z., Kronenberger, T., Küblbeck, J., Kinnen, F. J. M., Hesse, S. S., Malik, A., Kudolo, M., Niess, R., Gehringer, M., Zender, L., Witt-Enderby, P. A., Zlotos, D. P., & Laufer, S. A. (2022). Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 65(6), 4616–4632. https://doi.org/10.1021/acs.jmedchem.1c01646

Chicago

Abdelmalek, Carine M, Zexi Hu, Thales Kronenberger, Jenni Küblbeck, Franziska J M Kinnen, Salma S Hesse, Afsin Malik, et al. 2022. “Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.” Journal of Medicinal Chemistry 65 (6): 4616–32. doi:10.1021/acs.jmedchem.1c01646.